BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...
NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...
MedPage Today on MSN
Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer
Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...
The Brighterside of News on MSN
New drug combo cuts risk of death for men with prostate cancer by 40%
Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...
Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in ...
Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...
A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...
Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback